Fragile-X: neuropsychological test performance, CGG triplet repeat lengths, and hippocampal volumes.

per Jäkälä, P, Hänninen, T, Ryynänen, M, Laakso, M, Partanen, K, Mannermaa, A, Soininen, H
Publicat 1997

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.

per Pasanen, P. A., Eskelinen, M., Partanen, K., Pikkarainen, P., Penttilä, I., Alhava, E.
Publicat 1993

A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the di...

per Pasanen, P. A., Eskelinen, M., Partanen, K., Pikkarainen, P., Penttilä, I., Alhava, E.
Publicat 1994

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

per Pasanen, P. A., Eskelinen, M., Partanen, K., Pikkarainen, P., Penttilä, I., Alhava, E.
Publicat 1992

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele.

per Lehtovirta, M, Soininen, H, Laakso, M P, Partanen, K, Helisalmi, S, Mannermaa, A, Ryynänen, M, Kuikka, J, Hartikainen, P, Riekkinen, P J
Publicat 1996

Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients

per Jutila, L, Immonen, A, Mervaala, E, Partanen, J, Partanen, K, Puranen, M, Kalviainen, R, Alafuzoff, I, Hurskainen, H, Vapalahti, M, Ylinen, A
Publicat 2002

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a pa...

per Vassilev, L, Ranki, T, Joensuu, T, Jäger, E, Karbach, J, Wahle, C, Partanen, K, Kairemo, K, Alanko, T, Turkki, R, Linder, N, Lundin, J, Ristimäki, A, Kankainen, M, Hemminki, A, Backman, C, Dienel, K, von Euler, M, Haavisto, E, Hakonen, T, Juhila, J, Jäderberg, M, Priha, P, Vuolanto, A, Pesonen, S
Publicat a Oncoimmunology (2015)